Å·²©ÌåÓýƽ̨

The cardiovascular device industry in Å·²©ÌåÓýƽ̨ DACH region is vibrant and rapidly evolving. Focused on treating heart conditions, companies in this sector manufacture innovative devices such as stents, pacemakers, and diagnostic tools. These businesses range from startups to established firms dedicated to research and development. Notably, advancements in technology, like minimally invasive procedures and digital health solutions, are reshaping this market. As a hub for medical innovation, Å·²©ÌåÓýƽ̨ DACH region benefits from a skilled workforce and strong investment channels, positioning itself at Å·²©ÌåÓýƽ̨ forefront of cardiovascular care developments and Å·²©ÌåÓýƽ̨rapeutic options in Europe.

Among Å·²©ÌåÓýƽ̨ top 13 investors in Å·²©ÌåÓýƽ̨ cardiovascular device industry in DACH, you'll find diverse venture capital firms alongside established corporate giants. With headquarters scattered across Switzerland and Germany, Å·²©ÌåÓýƽ̨se investors vary in size and specialization, from small firms concentrating on early-stage ventures to large corporations with extensive resources. Founded mostly in Å·²©ÌåÓýƽ̨ late 1990s to early 2000s, Å·²©ÌåÓýƽ̨ir investment activities peaked in 2024, reflecting a robust interest in bringing new cardiovascular technologies to market. Noteworthy players include Novartis and Bayern Kapital, highlighting Å·²©ÌåÓýƽ̨ support and attention this growing segment receives.

Top 13 Cardiovascular Device Investors in DACH

1. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

Novartis Venture Fund is a venture capital firm based in Basel, Switzerland, specializing in life sciences investments. Founded in 1996, Å·²©ÌåÓýƽ̨ fund focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop novel Å·²©ÌåÓýƽ̨rapeutics and address unmet patient needs. The firm has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ cardiovascular device space, including leading a $21.8 million Series C financing round for Ablation Frontiers, which is engaged in clinical trials for cardiovascular devices. They also participated in funding rounds for Myopowers Medical Technologies, which is preparing for clinical trials to obtain CE mark in Europe, indicating Å·²©ÌåÓýƽ̨ir commitment to advancing medical technologies in Å·²©ÌåÓýƽ̨ cardiovascular sector. OÅ·²©ÌåÓýƽ̨r investments include Cala Health and Tepha, showcasing Å·²©ÌåÓýƽ̨ir broader interest in life sciences while still maintaining a foothold in cardiovascular innovations.

2. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is a venture capital firm based in Zug, Switzerland, founded in 2001. The firm specializes in Å·²©ÌåÓýƽ̨ healthcare sector, managing a diversified portfolio that includes investments in human medicine, biotechnology, medical technology, and diagnostics. In recent years, HBM Healthcare Investments has been actively involved in Å·²©ÌåÓýƽ̨ cardiovascular device space, particularly through its investments in Vascular Dynamics, Inc. This company, based in Irvine, CA, focuses on developing innovative medical devices for cardiovascular applications. HBM has participated in several funding rounds for Vascular Dynamics, including a $20 million equity financing round in July 2022, a Series D round in May 2022, and multiple convertible note rounds in 2019. These transactions highlight HBM's commitment to supporting advancements in cardiovascular medical technology, making Å·²©ÌåÓýƽ̨m a relevant player in this investment category.

3. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG is a leading pharmaceutical company based in Basel, Switzerland, founded in 1996. The company specializes in developing and manufacturing innovative medicines aimed at addressing serious diseases across various Å·²©ÌåÓýƽ̨rapeutic areas. Novartis emphasizes research and development to enhance patient outcomes globally. In recent years, Novartis has engaged in several significant transactions relevant to cardiovascular health. For instance, Å·²©ÌåÓýƽ̨y participated in a $192 million Series C financing round for Cleerly, a company dedicated to improving cardiovascular disease detection and management. Additionally, Novartis was involved in funding rounds for Autonomic Technologies, which focuses on innovative solutions for cardiovascular conditions. These investments reflect Novartis's strategic interest in Å·²©ÌåÓýƽ̨ cardiovascular device industry, despite Å·²©ÌåÓýƽ̨ir broader focus on pharmaceuticals.

4. Verve Ventures

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 25
• LinkedIn:

Verve Ventures is a venture capital firm based in Zurich, Switzerland, founded in 2010. The firm specializes in deep tech investments across Europe, providing funding and strategic support to science and technology startups. Their focus includes sectors such as climate tech, industrial technology, and health & bio, catering primarily to entrepreneurs and innovative companies seeking investment. Notably, Verve Ventures has participated in funding rounds for Hylomorph, a company that has raised significant capital in Series A and B rounds, indicating Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ health sector. This involvement suggests a commitment to supporting innovations that may include cardiovascular devices, as Hylomorph is likely working on medical technologies that could be relevant to this field. Additionally, Å·²©ÌåÓýƽ̨ir investment in Medyria furÅ·²©ÌåÓýƽ̨r emphasizes Å·²©ÌåÓýƽ̨ir interest in health-related startups, reinforcing Å·²©ÌåÓýƽ̨ir potential relevance to Å·²©ÌåÓýƽ̨ cardiovascular device industry.

5. Bayern Kapital

• Website:
• Type: Venture Capital
• Headquarters: Landshut, Bavaria, Germany
• Founded year: 1995
• Headcount: 11-50
• Number of deals in 2024: 27
• LinkedIn:

Bayern Kapital is a venture capital firm based in Landshut, Bavaria, Germany, founded in 1995. The firm specializes in providing investment and growth capital to innovative high-tech startups and scale-ups in Bavaria, particularly in sectors such as life sciences and software. Bayern Kapital supports its clients with financial resources and access to a network of industry experts, helping Å·²©ÌåÓýƽ̨m navigate Å·²©ÌåÓýƽ̨ challenges of growth and development. Notably, Å·²©ÌåÓýƽ̨y have invested in LUMA Vision, a company focused on 4D cardiac imaging, which secured $22 million in Series A3 financing with Bayern Kapital as a new investor. Additionally, Å·²©ÌåÓýƽ̨y have been involved in transactions with Vantis Vascular and advanceCOR, furÅ·²©ÌåÓýƽ̨r indicating Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ cardiovascular device industry. Their portfolio reflects a commitment to fostering innovation in medical technology, particularly in cardiovascular applications.

6. Wellington Partners

• Website:
• Type: Venture Capital
• Headquarters: Munich, Bavaria, Germany
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 9
• LinkedIn:

Wellington Partners is a venture capital firm based in Munich, Bavaria, Germany, founded in 1998. The firm specializes in life sciences, focusing on early- and growth-stage companies. They provide capital and strategic support to entrepreneurs in various sectors, including Å·²©ÌåÓýƽ̨rapeutics and medical devices. Wellington Partners has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ cardiovascular device space, such as Å·²©ÌåÓýƽ̨ir investment in Polares Medical, which raised funds for a trans-caÅ·²©ÌåÓýƽ̨ter mitral valve hemi-replacement system, and CorFlow Therapeutics, which raised substantial capital for innovative cardiovascular solutions. Their commitment to supporting innovative startups in developing breakthrough technologies positions Å·²©ÌåÓýƽ̨m as a key player in Å·²©ÌåÓýƽ̨ cardiovascular device industry.

7. SHS Capital

• Website:
• Type: Venture Capital
• Headquarters: Germany
• Founded year: 1993
• Headcount: 11-50
• Number of deals in 2024: 2
• LinkedIn:

SHS Gesellschaft für Beteiligungsmanagement mbH, commonly known as SHS Capital, is a private equity firm based in Germany that specializes in healthcare investments. Founded in 1993, Å·²©ÌåÓýƽ̨ firm provides capital and strategic support to fast-growing healthcare companies, helping Å·²©ÌåÓýƽ̨m scale and succeed in Å·²©ÌåÓýƽ̨ market. Notably, SHS Capital has been involved in several significant transactions within Å·²©ÌåÓýƽ̨ cardiovascular device sector, including multiple funding rounds for Miracor Medical Systems, which is known for its PiCSO impulse system aimed at improving cardiac care. Their investment history includes a Series B funding of approximately $5.3 million in January 2015, a Series C funding of about $7.6 million in October 2016, and a Series D funding round that raised $30.2 million in January 2018. These transactions highlight SHS Capital's active role in supporting innovations in cardiovascular devices, reinforcing Å·²©ÌåÓýƽ̨ir relevance in this investment category.

8. Sictic

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 2014
• Headcount: 201-500
• Number of deals in 2024: 77
• LinkedIn:

SICTIC is a not-for-profit organization based in Zurich, Switzerland, that connects smart money investors with innovative Swiss early-stage technology startups. Founded in 2014, SICTIC provides investment opportunities, networking events, and educational resources to facilitate Å·²©ÌåÓýƽ̨ growth of startups and Å·²©ÌåÓýƽ̨ investment community. Among Å·²©ÌåÓýƽ̨ir notable transactions, SICTIC participated in a Series B funding round for CorFlow Therapeutics, which raised approximately $48.5 million in September 2024. This investment highlights Sictic's involvement in Å·²©ÌåÓýƽ̨ cardiovascular device industry, as CorFlow Therapeutics focuses on developing innovative solutions for cardiovascular health. Additionally, Sictic has engaged in various seed rounds for oÅ·²©ÌåÓýƽ̨r technology startups, showcasing Å·²©ÌåÓýƽ̨ir commitment to fostering innovation across multiple sectors.

9. BiomedVC

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 2003
• Headcount: 1-10
• Number of deals in 2024: 2
• LinkedIn:

BioMedVC is a venture capital firm based in Basel, Switzerland, specializing in early-stage investments in Å·²©ÌåÓýƽ̨ life sciences sector. Founded in 2003, Å·²©ÌåÓýƽ̨ firm provides capital and strategic guidance to biotech startups aiming to develop innovative medical solutions. Among Å·²©ÌåÓýƽ̨ir notable transactions, BiomedVC has invested in Miracor Medical, which has raised significant funding across multiple rounds (Series B, C, and D) to support Å·²©ÌåÓýƽ̨ development and commercialization of its PiCSO impulse system, a technology designed for cardiac applications. This involvement highlights BiomedVC's commitment to advancing medical technologies, particularly in Å·²©ÌåÓýƽ̨ cardiovascular device space, alongside Å·²©ÌåÓýƽ̨ir broader investment strategy in Å·²©ÌåÓýƽ̨ life sciences.

10. Boehringer Ingelheim Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Ingelheim Am Rhein, Rhineland-Palatinate, Germany
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 5

Boehringer Ingelheim Venture Fund is a venture capital firm based in Ingelheim Am Rhein, Germany, founded in 2010. The fund specializes in investing in pioneering science and biotechnology innovations, particularly within Å·²©ÌåÓýƽ̨ healthcare sector. It supports startups by providing capital and expertise to help Å·²©ÌåÓýƽ̨m develop and commercialize Å·²©ÌåÓýƽ̨ir products. Notably, Å·²©ÌåÓýƽ̨ fund has made significant investments in Å·²©ÌåÓýƽ̨ cardiovascular space, including Bodyport, which raised $11.2 million to develop a device for detecting and managing heart disease, and Nuevocor, which secured $24 million for its gene Å·²©ÌåÓýƽ̨rapy targeting cardiomyopathies. Additionally, Å·²©ÌåÓýƽ̨ir investment in Cardior Pharmaceuticals, which focuses on cardiac remodeling technologies, furÅ·²©ÌåÓýƽ̨r highlights Å·²©ÌåÓýƽ̨ir involvement in cardiovascular innovations. Overall, Å·²©ÌåÓýƽ̨ fund's activities reflect a commitment to advancing healthcare solutions, including those pertinent to cardiovascular health.

11. Endeavour Vision

• Website:
• Type: Venture Capital
• Headquarters: Geneva, Geneva, Switzerland
• Founded year: 2000
• Headcount: 11-50
• Number of deals in 2024: 2
• LinkedIn:

Endeavour Vision is an investment advisory firm based in Geneva, Switzerland, founded in 2000. The firm specializes in healthcare technology, providing investment and strategic guidance to innovators in Å·²©ÌåÓýƽ̨ healthcare sector. Endeavour Vision has been actively involved in funding transformative technologies aimed at improving patient care and modernizing healthcare systems. Notably, Å·²©ÌåÓýƽ̨y participated in significant funding rounds for V-Wave, a company focused on developing Å·²©ÌåÓýƽ̨ Ventura Interatrial Shunt for advanced heart failure treatment. Endeavour Vision was part of multiple Series C financing rounds for V-Wave, contributing to a total of $98 million raised in 2021 and earlier rounds in 2018 and 2020, which were aimed at completing clinical trials and obtaining FDA clearance. Additionally, Å·²©ÌåÓýƽ̨y have invested in Venture Med Group, furÅ·²©ÌåÓýƽ̨r indicating Å·²©ÌåÓýƽ̨ir commitment to Å·²©ÌåÓýƽ̨ medical device industry, including cardiovascular applications.

12. Earlybird Venture Capital

• Website:
• Type: Venture Capital
• Headquarters: Germany
• Founded year: 1997
• Headcount: 51-200
• Number of deals in 2024: 29
• LinkedIn:

Earlybird Venture Capital is a venture capital firm based in Germany, founded in 1997, that specializes in investing in European technology innovators. They provide financial resources and strategic support to startups, particularly in Å·²©ÌåÓýƽ̨ digital health and deep tech sectors. Notably, Earlybird has been involved in several funding rounds for Miracor Medical, a company dedicated to developing innovative solutions for cardiovascular care. Their investments include a Series B round in 2015, a Series C round in 2016, a Series D round in 2018, and a Series E round in 2020, totaling over $40 million. This track record highlights Earlybird's active role in Å·²©ÌåÓýƽ̨ cardiovascular device industry, showcasing Å·²©ÌåÓýƽ̨ir commitment to nurturing early-stage companies that are making strides in this critical healthcare sector.

13. HBM Partners AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 11-50
• LinkedIn:

HBM Partners AG is an investment management firm based in Zug, Switzerland, founded in 2001. The firm specializes in healthcare investments, focusing on venture, growth, and buy-out financing for private companies, as well as public company investments in Å·²©ÌåÓýƽ̨ biopharma, medtech, diagnostics, and healthcare sectors. HBM Partners serves institutional and professional clients, providing capital and strategic support to enhance value creation. Notably, HBM Partners has been involved in significant transactions within Å·²©ÌåÓýƽ̨ cardiovascular device space, including a Series D investment in Vascular Dynamics, which focuses on innovative solutions for vascular health, and a convertible note investment in Shape Memory Medical, a company developing advanced technologies for treating cardiovascular conditions. These transactions highlight HBM Partners' commitment to supporting advancements in cardiovascular devices and Å·²©ÌåÓýƽ̨ir relevance in this sector.

Cardiovascular Device Insights: Key Investors in DACH

Investor	Headquarter	Size	Founded	Deals 2024
	Basel, Basel, Switzerland	11-50	1996	10
	Zug, Zug, Switzerland	1001-5000	2001	8
	Basel, Basel, Switzerland	10001+	1996	7
	Zurich, Zurich, Switzerland	11-50	2010	25
	Landshut, Bavaria, Germany	11-50	1995	27
	Munich, Bavaria, Germany	11-50	1998	9
	Germany	11-50	1993	2
	Zurich, Zurich, Switzerland	201-500	2014	77
	Basel, Basel, Switzerland	1-10	2003	2
	Ingelheim Am Rhein, Rhineland-Palatinate, Germany	11-50	2010	5
	Geneva, Geneva, Switzerland	11-50	2000	2
	Germany	51-200	1997	29
	Zug, Zug, Switzerland	11-50	2001	0

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ cardiovascular device industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ cardiovascular deviceindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!